Midostaurin (Rydapt) for Systemic Mastocytosis


( Last Updated : April 20, 2020)
Generic Name:
Midostaurin
Project Status:
Complete
Therapeutic Area:
Systemic Mastocytosis
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Brand Name:
Rydapt
Project Line:
Reimbursement Review
Project Number:
PC0193-000
NOC Status at Filing:
Post NOC
NOC Date:

Details


Strength:
25 mg
Tumour Type:
Other
Indications:
Systemic Mastocytosis
Funding Request:
For the treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL).
Sponsor:
Novartis Pharmaceuticals Canada Inc.
Submission Date:
Submission Deemed Complete:
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Do not reimburse
pERC Meeting:
Final Recommendation Issued:

Files

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.